前线达妥木单抗-VTd 与适合 ASCT 的多发性骨髓瘤的标准治疗的比较：匹配调整后的间接比较。
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
机构信息
Service d'Hématologie Clinique, University Hospital Hôtel-Dieu, Nantes 44000, France.
Institut Universitaire du Cancer-Oncopole & Centre de Recherches en Cancerologie de Toulouse, Toulouse 31100, France.
出版信息
Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24.
To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/OS) with D-VTd/VTd versus bortezomib/lenalidomide/dexamethasone (VRd), bortezomib/cyclophosphamide/dexamethasone (VCd) and bortezomib/dexamethasone (Vd). After matching adjustment, significant improvements in PFS were estimated for D-VTd versus VRd (hazard ratio [HR]: 0.47 [95% CI: 0.33-0.69]), VCd (HR: 0.35 [95% CI: 0.21-0.58]) and Vd (HR: 0.42 [95% CI: 0.28-0.63]). OS was significantly longer with D-VTd versus VRd (HR: 0.31 [95% CI: 0.16-0.57]), VCd (HR: 0.35 [95% CI: 0.14-0.86]) and Vd (HR: 0.38 [95% CI: 0.18-0.77]). No significant PFS/OS differences were seen for VTd versus other SoC. This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma.
比较达雷妥尤单抗联合标准治疗（SoC；硼替佐米/沙利度胺/地塞米松[VTd]）与单独 VTd 与其他 SoC 治疗适合移植的新诊断多发性骨髓瘤。我们进行了无锚定匹配调整的间接比较，以评估 D-VTd/VTd 与硼替佐米/来那度胺/地塞米松（VRd）、硼替佐米/环磷酰胺/地塞米松（VCd）和硼替佐米/地塞米松（Vd）相比，无进展生存期（PFS）和总生存期（OS）的差异。经过匹配调整，与 VRd、VCd 和 Vd 相比，D-VTd 显著改善了 PFS（风险比[HR]：0.47[95%置信区间：0.33-0.69]、0.35[95%置信区间：0.21-0.58]和 0.42[95%置信区间：0.28-0.63]）。与 VRd、VCd 和 Vd 相比，D-VTd 显著延长了 OS（HR：0.31[95%置信区间：0.16-0.57]、0.35[95%置信区间：0.14-0.86]和 0.38[95%置信区间：0.18-0.77]）。VTd 与其他 SoC 相比，PFS/OS 无显著差异。这项分析支持将达雷妥尤单抗作为适合移植的新诊断多发性骨髓瘤的一线治疗药物。
Zotero 插件